Chlordiazepoxide Hydrochloride

Depression, Enterocolitis, Anxiety Disorders + 6 more

Treatment

8 FDA approvals

20 Active Studies for Chlordiazepoxide Hydrochloride

What is Chlordiazepoxide Hydrochloride

Chlordiazepoxide

The Generic name of this drug

Treatment Summary

Chlordiazepoxide is a medication used to treat anxiety and symptoms associated with alcohol withdrawal. It is a type of benzodiazepine that also has sedative, anticonvulsant, and amnesic properties.

Librax

is the brand name

image of different drug pills on a surface

Chlordiazepoxide Hydrochloride Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Librax

Chlordiazepoxide

1966

112

Approved as Treatment by the FDA

Chlordiazepoxide, otherwise known as Librax, is approved by the FDA for 8 uses like Enterocolitis and Irritable Bowel Syndrome .

Enterocolitis

Used to treat acute Enterocolitis in combination with Clidinium

Irritable Bowel Syndrome

Used to treat Irritable Bowel Syndrome (IBS) in combination with Clidinium

Irritable Bowel Syndrome (IBS)

Used to treat Irritable Bowel Syndrome (IBS) in combination with Clidinium

acute Enterocolitis

Used to treat acute Enterocolitis in combination with Clidinium

Depression

Used to treat Depression in combination with Amitriptyline

Peptic Ulcer Disease

Used to treat Peptic Ulcer Disease in combination with Clidinium

Anxiety

Used to treat moderate to severe anxiety in combination with Amitriptyline

moderate to severe symptoms

Used to treat moderate to severe symptoms in combination with Amitriptyline

Effectiveness

How Chlordiazepoxide Hydrochloride Affects Patients

Chlordiazepoxide is a drug used to reduce anxiety, induce sedation, and act as a mild pain reliever. It works by blocking electrical signals in the brain stem that cause arousal. Studies have shown that it can also have an effect on the brain's limbic system, which is responsible for emotions. It has been seen to make hostile monkeys tame, and to reduce fear and aggression in rats with brain lesions. It can be effective at low doses that don't cause sedation.

How Chlordiazepoxide Hydrochloride works in the body

Chlordiazepoxide works by increasing the binding of the neurotransmitter GABA to the GABA receptor in the brain. This increases the inhibitory effects of GABA, leading to sedation, relaxation, and a reduction in anxiety.

When to interrupt dosage

The proposed measure of Chlordiazepoxide Hydrochloride is contingent upon the determined affliction, including Syndrome, moderate to extreme indications and Depression. The quantity of dosage varies, depending on the technique of delivery outlined in the table beneath.

Condition

Dosage

Administration

moderate to severe symptoms

, 5.0 mg, 10.0 mg, 25.0 mg

, Oral, Capsule, Capsule - Oral, Capsule, gelatin coated - Oral, Capsule, gelatin coated, Tablet, Tablet - Oral, Tablet, film coated - Oral, Tablet, film coated

Depression

, 5.0 mg, 10.0 mg, 25.0 mg

, Oral, Capsule, Capsule - Oral, Capsule, gelatin coated - Oral, Capsule, gelatin coated, Tablet, Tablet - Oral, Tablet, film coated - Oral, Tablet, film coated

Enterocolitis

, 5.0 mg, 10.0 mg, 25.0 mg

, Oral, Capsule, Capsule - Oral, Capsule, gelatin coated - Oral, Capsule, gelatin coated, Tablet, Tablet - Oral, Tablet, film coated - Oral, Tablet, film coated

Anxiety Disorders

, 5.0 mg, 10.0 mg, 25.0 mg

, Oral, Capsule, Capsule - Oral, Capsule, gelatin coated - Oral, Capsule, gelatin coated, Tablet, Tablet - Oral, Tablet, film coated - Oral, Tablet, film coated

Irritable Bowel Syndrome

, 5.0 mg, 10.0 mg, 25.0 mg

, Oral, Capsule, Capsule - Oral, Capsule, gelatin coated - Oral, Capsule, gelatin coated, Tablet, Tablet - Oral, Tablet, film coated - Oral, Tablet, film coated

Peptic Ulcer Disease

, 5.0 mg, 10.0 mg, 25.0 mg

, Oral, Capsule, Capsule - Oral, Capsule, gelatin coated - Oral, Capsule, gelatin coated, Tablet, Tablet - Oral, Tablet, film coated - Oral, Tablet, film coated

Syndrome

, 5.0 mg, 10.0 mg, 25.0 mg

, Oral, Capsule, Capsule - Oral, Capsule, gelatin coated - Oral, Capsule, gelatin coated, Tablet, Tablet - Oral, Tablet, film coated - Oral, Tablet, film coated

Anxiety

, 5.0 mg, 10.0 mg, 25.0 mg

, Oral, Capsule, Capsule - Oral, Capsule, gelatin coated - Oral, Capsule, gelatin coated, Tablet, Tablet - Oral, Tablet, film coated - Oral, Tablet, film coated

Anxiety

, 5.0 mg, 10.0 mg, 25.0 mg

, Oral, Capsule, Capsule - Oral, Capsule, gelatin coated - Oral, Capsule, gelatin coated, Tablet, Tablet - Oral, Tablet, film coated - Oral, Tablet, film coated

Warnings

There are 20 known major drug interactions with Chlordiazepoxide Hydrochloride.

Common Chlordiazepoxide Hydrochloride Drug Interactions

Drug Name

Risk Level

Description

Azelastine

Major

Chlordiazepoxide may increase the central nervous system depressant (CNS depressant) activities of Azelastine.

Deutetrabenazine

Major

The risk or severity of sedation and somnolence can be increased when Chlordiazepoxide is combined with Deutetrabenazine.

Ethanol

Major

Chlordiazepoxide may increase the central nervous system depressant (CNS depressant) activities of Ethanol.

Methadone

Major

Chlordiazepoxide may increase the central nervous system depressant (CNS depressant) activities of Methadone.

Oliceridine

Major

The risk or severity of hypotension, sedation, death, somnolence, and respiratory depression can be increased when Chlordiazepoxide is combined with Oliceridine.

Chlordiazepoxide Hydrochloride Toxicity & Overdose Risk

The lowest toxic dose of the drug in rats has been found to be 537mg/kg when taken orally. Overdosing on this drug can cause slowed breathing, muscle weakness, and drowsiness.

image of a doctor in a lab doing drug, clinical research

Chlordiazepoxide Hydrochloride Novel Uses: Which Conditions Have a Clinical Trial Featuring Chlordiazepoxide Hydrochloride?

Currently, 794 active trials are investigating the effectiveness of Chlordiazepoxide Hydrochloride in ameliorating Anxiety Disorders, moderate to severe associated symptoms and Syndrome.

Condition

Clinical Trials

Trial Phases

Anxiety Disorders

49 Actively Recruiting

Phase 2, Not Applicable, Phase 4, Phase 3, Early Phase 1

Enterocolitis

0 Actively Recruiting

Irritable Bowel Syndrome

4 Actively Recruiting

Not Applicable, Early Phase 1

Syndrome

4 Actively Recruiting

Phase 2, Phase 3, Not Applicable

Peptic Ulcer Disease

0 Actively Recruiting

Anxiety

2 Actively Recruiting

Not Applicable

Anxiety

0 Actively Recruiting

Depression

288 Actively Recruiting

Not Applicable, Phase 1, Phase 2, Early Phase 1, Phase 4, Phase 3

moderate to severe symptoms

0 Actively Recruiting

Chlordiazepoxide Hydrochloride Reviews: What are patients saying about Chlordiazepoxide Hydrochloride?

5

Patient Review

1/12/2014

Chlordiazepoxide Hydrochloride for Symptoms from Alcohol Withdrawal

I felt great while taking this medication, but unfortunately my old anxieties came back with a vengeance after I tapered off. I'm told that the drug can't be taken for long periods of time.

5

Patient Review

5/28/2016

Chlordiazepoxide Hydrochloride for Symptoms from Alcohol Withdrawal

This treatment is really effective in helping you through the tough initial withdrawals. The only downside I experienced was feeling very tired and fuzzy-headed while on it; although, I will say that I slept like a baby.

5

Patient Review

11/28/2012

Chlordiazepoxide Hydrochloride for Symptoms from Alcohol Withdrawal

I felt noticeably better after taking this medication. I was able to get through my day with more energy and less anxiety.

4.7

Patient Review

6/8/2015

Chlordiazepoxide Hydrochloride for Symptoms from Alcohol Withdrawal

I started using this to help me drink less alcohol.

4.7

Patient Review

2/22/2010

Chlordiazepoxide Hydrochloride for Anxious

The only downside I experienced was some dizziness and dry mouth.

4.3

Patient Review

6/3/2014

Chlordiazepoxide Hydrochloride for Symptoms from Alcohol Withdrawal

The medication was very effective in helping me detox. I think a higher dosage for a longer period of time would have been beneficial, but it is essential that someone commits to abstaining from the drug they are detoxing from.

3.3

Patient Review

12/18/2009

Chlordiazepoxide Hydrochloride for Severe Anxiety

3.3

Patient Review

4/14/2011

Chlordiazepoxide Hydrochloride for Severe Anxiety

I'm still drinking.

1.7

Patient Review

1/31/2010

Chlordiazepoxide Hydrochloride for Symptoms from Alcohol Withdrawal

image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about chlordiazepoxide hydrochloride

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is chlordiazepoxide an antidepressant?

"Chlordiazepoxide belongs to a class of medications called benzodiazepines/anticonvulsants.

This product contains two medicines, amitriptyline and chlordiazepoxide, which are used to treat mental and mood disorders, such as depression with anxiety symptoms. Amitriptyline is a tricyclic antidepressant, while chlordiazepoxide is a benzodiazepine/anticonvulsant."

Answered by AI

Is chlordiazepoxide used for sleep?

"Librium is thegeneric name for Chlordiazepoxide, a sedative-hypnotic Benzodiazepine. The effects of Librium are similar to the effects of Xanax, Valium, and Ativan. A proper dose of Librium will relieve a person's anxiety and help them sleep through the night."

Answered by AI

What is chlordiazepoxide hydrochloride used for?

"Chlordiazepoxide is a medication used to relieve symptoms of anxiety or nervousness before surgery, as well as symptoms of alcohol withdrawal. It is a benzodiazepine."

Answered by AI

How does chlordiazepoxide make you feel?

"Chlordiazepoxide affects the way neurotransmitters pass messages to your brain cells, creating a calming effect. This can be helpful for people with anxiety, for whom the drug is sometimes prescribed."

Answered by AI

Clinical Trials for Chlordiazepoxide Hydrochloride

Image of Michael E. DeBakey VA Medical Center, Houston, TX in Houston, United States.

Acceptance and Commitment Therapy for Inflammatory Bowel Disease

18+
All Sexes
Houston, TX

Many Veterans with gastrointestinal disorders, such as inflammatory bowel disease (IBD), also have mental health conditions. IBD and mental health conditions can worsen one another through the brain-gut axis, leading to dramatic deficits in psychosocial functioning and quality of life (QOL). Yet, few Veterans with comorbid IBD and mental health conditions receive psychotherapy and no evidence-based psychotherapies have been tested in Veterans with these comorbidities. Adapting brief acceptance and commitment therapy (ACT) to the specific to the needs of these patients and embedding treatment into routine gastroenterology care may increase Veterans' access to efficient and effective rehabilitative care. This study aims to adapt and test an integrated, 1-Day ACT intervention tailored to the specific needs of Veterans with IBD and mental health conditions to improve psychosocial functioning and QOL.

Waitlist Available
Has No Placebo

Michael E. DeBakey VA Medical Center, Houston, TX

Mackenzie Lynmarie Shanahan, PhD

Image of University of Michigan in Ann Arbor, United States.

Virtual Reality for Depression in Multiple Sclerosis

18+
All Sexes
Ann Arbor, MI

This trial explores the use of immersive virtual reality (VR) nature-based experiences as a supplementary treatment for depression in individuals with progressive multiple sclerosis (MS). This study will evaluate the feasibility and efficacy of at-home VR deployment using the Apple Vision Pro, an advanced device that offers enhanced resolution, immersion, and usability compared to earlier VR systems. The study hypotheses include: * The integration of VR nature-based experiences with standard care will be feasible, acceptable, and will result in greater reductions in depressive symptoms compared to standard care or VR-only interventions. * The integration of VR nature-based experiences with standard care will result in greater reductions in stress and anxiety, better sleep, less insomnia, and improved fatigue compared to standard care alone or VR-only interventions.

Recruiting
Has No Placebo

University of Michigan

Hala Darwish, PhD

Apple Inc.

Image of Medical University of South Carolina (MUSC), Brain Stimulation Laboratory Institute of Psychiatry in Charleston, United States.

Mindfulness Training for Depression

18 - 70
All Sexes
Charleston, SC

This NIH-funded single-arm pilot tests the feasibility, acceptability, and preliminary effects of embedding brief guided mindfulness practice (via the Healthy Minds smartphone app) into the inter-session intervals of clinically administered accelerated intermittent theta-burst stimulation (aiTBS) for major depressive disorder (MDD). Participants receive aiTBS as standard clinical care at MUSC; the research intervention is daily guided mindfulness practice during the aiTBS course. Outcomes include feasibility/acceptability, changes in state mindfulness and hedonic tone (Day 0 to Day 5), perceived ease of meditation, trait mindfulness at 4 and 12 weeks, and durability of antidepressant response (PHQ-9) at 4 and 12 weeks.

Waitlist Available
Has No Placebo

Medical University of South Carolina (MUSC), Brain Stimulation Laboratory Institute of Psychiatry

Clayton Olash, MD

Have you considered Chlordiazepoxide Hydrochloride clinical trials?

We made a collection of clinical trials featuring Chlordiazepoxide Hydrochloride, we think they might fit your search criteria.
Go to Trials
Image of University of South Florida in Tampa, United States.

Web-Based Program for Parenting Stress

18+
All Sexes
Tampa, FL

The goal of this clinical trial is to evaluate the feasibility, usability, and preliminary benefits of implementing ACT Together for parents of children with disabilities in pediatric outpatient clinics. ACT Together includes six self-paced, web-based modules and brief weekly one-on-one coaching sessions led by a trained occupational therapist. The program is based on acceptance and commitment therapy (ACT), which teaches practical skills to help people handle stress and difficult thoughts or feelings while taking steps toward what matters to them. The main questions this study aims to answer are: * Can parents and occupational therapists complete the study activities as planned (e.g., module completion, coaching sessions, and surveys)? * Is the program usable and acceptable/appropriate/feasible to implement in this setting? * Do parents show improvements in mental health and coping-related outcomes after participating in the program? * What are the experiences and perspectives of parents and therapists regarding the program? Parents as participants will: * Complete six self-paced web-based modules and brief weekly individual coaching sessions with a trained occupational therapist. * Complete online questionnaires before starting and after completing the program. * Take part in one online interview about their experiences and perspectives on the program. Occupational therapists as participants will: * Complete therapist training materials and deliver brief individual coaching sessions to parent participants, including completing a post-session checklist. * Complete brief online questionnaires before starting and after delivering the program. * Take part in one online interview about their experiences and perspectives on the program.

Waitlist Available
Has No Placebo

University of South Florida

Areum Han, PhD

Image of Worcester Recovery Center and Hospital in Worcester, United States.

Changing Lives and Changing Outcomes-9 for Serious Mental Illness

18+
All Sexes
Worcester, MA

People with serious mental illness (depression, bipolar, and schizophrenia spectrum disorders) have high rates of repeated criminal legal involvement and psychiatric hospitalizations. Longstanding research shows that in addition to treating clients' symptoms of mental illness, targeting risk factors for legal involvement can help reduce their chances of future incarcerations. Because hospitals are becoming increasingly forensic, treatment programs that address both mental illness and risk factors for legal involvement may be especially helpful in a state hospital setting, like Worcester Recovery Center and Hospital (WRCH). This treatment study offers an adjunctive 9-session intervention, Changing Lives and Changing Outcomes-9 (CLCO-9), for patients at WRCH; this program is designed to help people with serious mental illness who are involved in the legal system increase their awareness of their mental health and reduce their chances of future legal involvement. The investigators are proposing a treatment study testing the use of the CLCO-9 group intervention with patients with serious mental illness with current or previous criminal legal involvement at Worcester Recovery Center and Hospital (WRCH). The study has three aims: 1. Evaluate feasibility, fidelity, and patient satisfaction during the implementation of the CLCO-9 group treatment at WRCH 2. Evaluate CLCO-9's effectiveness on improving patient's self-reported mental health, and behavioral indicators of mental health and risk factors for legal involvement 3. Explore changes in WRCH clinicians' knowledge and attitudes about treating risk factors for criminal legal involvement. To test these aims, the research team will employ a two-phase study. In the first phase, the researchers will implement the intervention and make necessary adjustments to maximize the success of the implementation. In the second phase, the researchers will evaluate the treatment program's effectiveness in producing change from pre- to post-treatment. All patient participants in this study will receive the intervention. The projected sample size is about 20 treatment completers and 4 to 8 group leaders.

Waitlist Available
Has No Placebo

Worcester Recovery Center and Hospital

Faith Scanlon, PhD

Image of Stanford University School of Medicine in Stanford, United States.

BEAR Program for Suicidal Thoughts

18 - 75
Female
Stanford, CA

The current study aims to test the feasibility of a new form of group therapy for women who have a history of interpersonal trauma and current suicidal ideation. The Building Empowerment and Resilience (BEAR) Therapeutic group has been adapted for women who have experienced trauma and have current suicidal ideation. It incorporates psychological skills, psychoeducation about trauma and gender-based violence, and physical self-defense training, all within a therapeutic process. It will be implemented with women who have experienced interpersonal trauma (physical, sexual, or emotional abuse/neglect) and experience various mental health difficulties, including suicidal ideation. We aim to assess the feasibility to recruit and implement the BEAR group. Our ultimate aim is to assess whether the program can effect self-efficacy and suicidal ideation.

Waitlist Available
Has No Placebo

Stanford University School of Medicine

Jennifer Keller, PhD

Have you considered Chlordiazepoxide Hydrochloride clinical trials?

We made a collection of clinical trials featuring Chlordiazepoxide Hydrochloride, we think they might fit your search criteria.
Go to Trials
Image of University of South Florida in Tampa, United States.

WeACT Program for Caregivers of People With Dementia

18+
All Sexes
Tampa, FL

The goal of this clinical trial is to learn whether WeACT, a self-paced, web-based program, is feasible and helpful for adult family caregivers of a relative living with dementia. WeACT is based on acceptance and commitment therapy (ACT), which teaches skills to handle difficult thoughts and feelings and take steps toward what matters most. The main questions this study aims to answer are: * Can caregivers complete WeACT as planned? * Do caregivers show improvements in mental health and coping after using WeACT? * What are caregivers' experiences with the program, and what suggestions do they have to improve it? Participants will: * Complete six self-paced weekly online modules and use the daily practice section during the program. * Complete online questionnaires before starting and after completing the program. * Take part in one online interview about their experience.

Waitlist Available
Has No Placebo

University of South Florida

Areum Han

Image of Fred Hutch/University of Washington Cancer Consortium in Seattle, United States.

Psilocybin Therapy for Anxiety and Depression in Cancer

18 - 85
All Sexes
Seattle, WA

This phase II trial tests the safety, side effects and how well group retreat psilocybin therapy works for the treatment of anxiety and depression in patients with solid tumors that have spread from where they first started (primary site) to other places in the body (metastatic) or with hematologic cancers for which no treatment is currently available (incurable). For patients with metastatic, incurable cancer, unrelieved anxiety and existential distress can cause profound suffering. Psilocybin therapy can relieve anxiety and existential distress by disrupting patterns of thinking that contribute to anxiety and depression. Psilocybin is a substance being studied in the treatment of anxiety or depression in patients with cancer. In this study, a pharmaceutical grade of psilocybin will be used that has been approved by the FDA for research, provided by Filament Health. Psilocybin acts on the brain by resetting the brain's activity and increasing connections between brain regions, particularly those involved in mood regulation and self-perception. In this study psilocybin is combined with structured discussions and reflections that enable patients to have new insights about their situation. In a prior study, group retreat psilocybin therapy was proven to be safe and this study tests a refined dosing regimen for symptoms of anxiety and depression in patients with metastatic solid tumors or incurable hematologic malignancies.

Phase 2
Waitlist Available

Fred Hutch/University of Washington Cancer Consortium

Anthony Back, MD

Image of Wahwala Iyohlogya/Peaceful Means in Pine Ridge, United States.

Lakota Family Acceptance Program for Depression and Anxiety

Any Age
All Sexes
Pine Ridge, SD

The goal of this open pilot trial (OPT) is to develop a Lakota-adapted Family Acceptance Project (LFAP) for Indigenous 2SLGBTQ+ youth and their caregivers. The OPT is specifically focused on acceptability, feasibility, and safety of programming and research protocols. The investigators will also examine pre- to post- changes on outcomes for the sole purposes of making sure scores on measures are changing in the hypothesized direction (e.g., depression scores are going from moderate to minimal as opposed to no change or depression scores increasing). Once enrolled in the study, participants complete a baseline survey. Then participants will engage in LFAP which is an 8-session group intervention; sessions will be scheduled once a week for eight weeks (at 2 hours per session). Participants will complete survey instruments before and immediately after the program sessions, in addition to post-program surveys and an exit interview.

Recruiting
Has No Placebo

Wahwala Iyohlogya/Peaceful Means (+1 Sites)

Katie Edwards, PhD

Have you considered Chlordiazepoxide Hydrochloride clinical trials?

We made a collection of clinical trials featuring Chlordiazepoxide Hydrochloride, we think they might fit your search criteria.
Go to Trials